Latest News and Press Releases

UPPSALA, SWEDEN – LIDDS AB (publ) announces that the dose escalation in the Phase I study NZ-DTX is proceeding according to the protocol, with additional patients being treated at a higher dose level...

UPPSALA, SWEDEN – LIDDS AB (publ) has performed preclinical studies using a TLR9 agonist formulated with NanoZolid® (NZ-TLR9) showing that a single NZ-TLR9 injection is reducing tumor growth and...

UPPSALA, SWEDEN – LIDDS AB (publ) - LIDDS CEO, Monica Wallter, will present the company at the Redeye Fight Cancer Seminar taking place in Stockholm on March 10, targeting both private and...

OKTOBER – DECEMBER 2019 Nettoomsättningen uppgick till MSEK 0,0 (0,0)Kostnaderna uppgick till MSEK -15,1 (-4,9)Resultatet före och efter skatt uppgick till MSEK -15,1 (-4,9)Resultat per aktie uppgick...

The board of directors of LIDDS AB has decided to carry out a directed issue of 467,783 shares at a subscription price of SEK 17 per share. LIDDS will through the directed share issue receive proceeds...

UPPSALA, SWEDEN. LIDDS AB (publ) – The National Cancer Institute in Vilnius, Lithuania, has enrolled and dosed their first patient. The aim of the phase I dose escalation clinical trial is to assess...

UPPSALA, SWEDEN. LIDDS AB (publ) - The last patient has been dosed in the voluntary open-label extension (OLE) of LPC-004. This means that all patients included in the clinical study have been dosed....

UPPSALA, SWEDEN – LIDDS AB (publ) today announces that the United States Patent and Trademark Office has registered the trademark NanoZolid. LIDDS thereby has exclusive rights to the trademark for...

UPPSALA, SWEDEN – LIDDS AB (publ)In a novel analysis by Stockpicker, an independent Swedish financial firm focusing on stock and fund analysis, LIDDS is listed as one of twelve interesting shares to...

UPPSALA, SWEDEN – LIDDS AB (publ) today announces that the United States Patent and Trademark Office has approved a novel product patent on NanoZolid pharmaceutical formulations. The novel patent...